Applications

1440.1 – PD-L1 testing for access to pembrolizumab in treatment naïve patients with locally advanced or metastatic non-small cell lung cancer

Find out about the service or technology in this application and the medical condition it addresses. You can also view the application documents, the deadlines for providing consultation input and the outcome of the application when the MSAC process is complete.

  • Status Complete
  • Type Re-application
  • Pre-PASC consultation -
  • Pre-MSAC consultation -
  • Outcome Supported

Application details

Reason for application

New MBS item.

Service or technology in this application

ImmunoHistoChemistry test for evaluation of Programmed Cell Death Ligand 1 (PD-L1) expression to determine eligibility for treatment with pembrolizumab.

Type: Investigative

Medical condition this application addresses

Locally advanced or metastatic non-small cell lung cancer.

Previous applications

1440 – PD-L1 testing for access to pembrolizumab in treatment na?ve patients with locally advanced or metastatic non-small cell lung cancer

Application documents

Public summary document

We aim to provide documents in an accessible format. If you're having problems using a document with your accessibility tools, please contact us for help.

Meetings to consider this application

  • PASC meeting: -
  • ESC meeting: -
  • MSAC meeting: 
    • 23 November 2017
    • 28-29 March 2018
    • 26-27 July 2018